RTW Venture Fund Limited Monthly Valuation Update & Factsheet (1612Z)

TIDMRTW

RNS Number : 1612Z

RTW Venture Fund Limited

12 May 2023

LEI: 549300Q7EXQQH6KF7Z84

12 May 2023

RTW Venture Fund Limited

Monthly Valuation Update & Factsheet

+13% NAV movement

RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 30 April 2023 (the "NAV") was US$358.6 million, or US$1.69 per ordinary share, an increase of 13% from the previous month.

The monthly factsheet is available on the Company's website:

https://www.rtwfunds.com/rtw-venture-fund-ltd/factsheets-letters/

For Further Information:

 
 RTW Investments, LP                                 [phone] 
 Woody Stileman, Managing Director 
  Krisha McCune, Director, Client Service 
 
 Buchanan                                            [phone] 
 Charles Ryland 
 Henry Wilson 
 George Beale 
 
 Numis                                               [phone] 
 Freddie Barnfield 
 Nathan Brown 
 Euan Brown 
 
 BofA Securities                                     [phone] 
 Edward Peel 
 Kieran Millar 
 
 Elysium Fund Management Limited                     [phone] 
 Joanna Duquemin Nicolle, Chief Executive Officer 
 Sadie Morrison, Managing Director 
 
 Morgan Stanley Fund Services USA LLC                [phone] 
 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DOCBLGDUGGBDGXB

(END) Dow Jones Newswires

May 12, 2023 02:00 ET (06:00 GMT)